Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Mean number of paracentesis between the 2 groups over a 6 months period
研究概览
简要总结
Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first step treatment. Refractory ascites (not responding to first step treatment) is treated with repeated large volume paracentesis followed by intra venous albumin expansion. In pilot studies vasoconstrictor agents such as terlipressin have shown beneficial effect on ascites production. Therefore the investigators will study the effect of combined therapy with albumin and terlipressin on recidivation ascites.
详细描述
About 30% of cirrhotic patients will develop ascites. Sodium restriction and diuretics are the first step treatment. Total paracentesis is used in patients with cirrhosis and tense ascites. Paracentesis alone was found to induce a decrease in effective arterial blood volume. This circulatory dysfunction may induce inhospital complications such as impaired renal function or hyponatremia and is associated with a significant reduction in long term survival. Intravenous albumin administration after paracentesis has been shown to prevent the post paracentesis decrease in arterial blood volume. Paracentesis also induces arteriolar vasodilation which plays a major role in initiating the decrease in arterial blood volume. Therefore, administration of a vasoconstrictor may decrease paracentesis induced arteriolar vasodilation and prevent the resulting decrease in effective arterial blood volume. Two randomised pilot studies suggest that Terlipressin may be as effective as intravenous albumin in preventing a decrease in effective arterial blood volume in patients with cirrhosis treated by paracentesis for tense ascites. The combined treatment, albumin plus terlipressin, could have additional effect and may improve ascites in such patients. In several studies the combined therapy, albumin plus terlipressin, has shown beneficial effect in cirrhotic patients with hepatorenal syndrome characterized by a sever decrease in arterial blood volume and vasodilation. In these studies, combined therapy was well tolerated.The aim of this study is to compare ascites relapse between two groups of cirrhotic patients with recidivation ascites treated by paracentesis and intravenous albumin perfusion plus terlipressin or placebo. In this double blind randomized multi-center trial, all patients receive albumin perfusion at the dose 8 g/l of removed ascites and Terlipressin (1mg) or placebo, administrated before and at the end of the paracentesis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged 18 years old and more with cirrhosis and refractory ascites define by the international ascites club.
- •Vital status non engaged in the 2 months
排除标准
- •cardiovascular disease : previous or actual angina pectoralis, myocardial infarction, heart failure, rhythm or conduction disorders, repolarisation abnormality on ECG
- •respiratory disease: previous or actual chronic pulmonary insufficiency, asthma
- •uncontrolled hypertension
- •acute portal vein thrombosis (less then 3 months) or currently treated.
- •chronic renal insufficiency (creatin > 15 mg/L)
- •severe hepatic encephalopathy
- •Alcoholic hepatitis or gastrointestinal bleeding in the last 3 months
- •hepatocellular carcinoma
- •severe illness with life threatening
- •pregnant or breastfeeding women
研究组 & 干预措施
Terlipressin
干预措施: Terlipressin (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Mean number of paracentesis between the 2 groups over a 6 months period
时间窗: 6 months
次要结局
- Number of cirrhosis complications groups(6 months)
- Mean number of days of hospitalization(6 months)
- Total ascites retrieval(6 months)
- Terlipressin safety(6 months)
- Liver transplantation and deaths(6 months)
- Delay between inclusion and the first rehospitalisation for ascites retrieval(6 months)